Debra Schwab Brandt, DO

Clinician in Medicine (Hematology)

Patient Care

Accepts new patients? Yes
Patient Type:
Referrals: Not Applicable

Patient Care Organizations

Cancer Center, Yale

Medical Oncology

Yale Medical Group

Board Certifications

  • Internal Medicine AB of Internal Medicine (1995)

  • Hematology (Internal Medicine) AB of Internal Medicine (1999)

  • Medical Oncology AB of Internal Medicine (1998)

Clinical Trials

Conditions Study Title
Pancreas E2211: A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors
Multiple Myeloma A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
Pancreas A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study)
Breast - Female NSABP B-42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed By an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer (CIRB)
Breast - Female, Breast - Male B55: A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
Lung A Phase 1b/2 Study of OMP-59R5 in Combination with Etoposide and Platinum Therapy in Subjects with Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE: Phase 1b/2 INvestigation of anti-Notch Antibody Therapy with Cisplatin and Etoposide in Small Cell Lung Carcinoma Safety and Efficacy)
Colon, Rectum A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies.
Multiple Myeloma S1304, A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease
Leukemia, other A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
Lung A Phase III, Randomized, Open-label, Crossover, Multi-center, Safety and Efficacy Study to Evaluate NAB-PACLITAXEL (ABRAXANE®) as Maintenance Treatment After Induction with NAB-PACLITAXEL plus Carboplatin in Subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC)
Lung S1400: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Breast - Female A neoadjuvant phase II trial of aromatase inhibitors in combination with everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancers with low and intermediate risk (less than or equal to 25) Oncotype Dx Recurrence Scores
Lymphoid Leukemia E1912: A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
Leukemia, other (E1910) A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults
Breast - Female, Breast - Male A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)
Breast - Female, Breast - Male A Randomized, Multicenter, Open-label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine versus Trastuzumab as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer who have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes following Preoperative Therapy (NSABP B50/Katherine Study)
Breast - Female, Breast - Male Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer (S1207)
Breast - Female A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less (SWOG S1007) (CIRB)
Colon A Phase II Multi-center, Randomized, Placebo-Controlled Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer

Edit this profile

Contact Info

Debra Schwab Brandt, DO
Patient Care Locations
Smilow Cancer Care - Sharon
19 West Main Street

Sharon, CT 06069
Smilow Cancer Care - Torrington
200 Kennedy Drive

Torrington, CT 06790
Mailing Address
PO Box 208028
New Haven, CT 06520-8028